Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

被引：14
|
作者：
Jones, Jeffrey [1 ]
Andritsos, Leslie [2 ]
Kreitman, Robert J. [3 ]
Ravandi, Farhad [4 ]
Schiffer, Charles [5 ]
Call, Timothy G. [6 ]
Lozanski, Gerard [7 ]
Harris, Pamela [8 ]
Sexton, Jennifer [2 ]
Ruppert, Amy S. [2 ]
Grever, Michael R. [2 ]
机构：
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA
[2] Ohio State Univ, Div Hematol, Columbus, OH USA
[3] Natl Canc Inst, Natl Inst Hlth, Mol Biol Lab, Bethesda, MD USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[5] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] Ohio State Univ, Dept Pathol, Columbus, OH USA
[8] Natl Canc Inst, Canc Therapy Evaluat Program, Rockville, MD USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1215.1215
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1215
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL
    Sivina, Mariela
    Kreitman, Robert J.
    Arons, Evgeny
    Buggy, Joseph J.
    Ravandi, Farhad
    Burger, Jan A.
    BLOOD, 2012, 120 (21)
  • [22] A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia
    Treon, Steven Peter
    Tripsas, Christina K.
    Yang, Guang
    Cao, Yang
    Xu, Lian
    Hunter, Zachary
    Cropper, Steven J.
    Mostyn, Patrick
    Meid, Kirsten
    Warren, Diane
    Patterson, Christopher
    Varma, Gaurav
    Laubach, Jacob P.
    Paba-Prada, Claudia E.
    Kunsman, Janet
    Ghobrial, Irene M.
    Kanan, Sandra
    Advani, Ranjana H.
    Palomba, Maria Lia
    BLOOD, 2013, 122 (21)
  • [23] LONG-TERM EFFICACY AND SAFETY WITH ORAL BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
    Kuter, David J.
    Gernsheimer, Terry
    Ghanima, Waleed
    Khan, Umer
    Ward, Brad
    Daak, Ahmed
    Cooper, Nichola
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 71 - 71
  • [24] Disorders of Platelet Number or Function: Clinical and Epidemiological Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia
    Cooper, Nichola
    Jansen, A. J. Gerard
    Bird, Robert
    Mayer, Jiri
    Sholzberg, Michelle
    Tarantino, Michael D.
    Garg, Mamta
    Ypma, Paula F.
    McDonald, Vickie
    Percy, Charles
    Kostal, Milan
    Goncalves, Isaac
    Bogdanov, Lachezar H.
    Gernsheimer, Terry B.
    Diab, Remco
    Yao, Mengjie
    Daak, Ahmed
    Kuter, David J.
    BLOOD, 2023, 142
  • [25] THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR IBRUTINIB COMBINED WITH BENDAMUSTINE AND RITUXIMAB IS ACTIVE AND TOLERABLE IN PATIENTS WITH RELAPSED/REFRACTORY CLL, INTERIM RESULTS OF A PHASE IB/II STUDY
    Brown, J.
    Barrientos, J.
    Flinn, I.
    Barr, P.
    Burger, J.
    Navarro, T.
    James, D.
    Hedrick, E.
    Friedberg, J.
    O'Brien, S.
    HAEMATOLOGICA, 2012, 97 : 218 - 218
  • [26] OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDERGOING NON-MYELOABLATIVE ALLOGENIC STEM CELL TRANSPLANTATION AFTER TREATMENT WITH THE BRUTON TYROSINE KINASE INHIBITOR IBRUTINIB
    Ramdohr, F.
    Franke, G. -N.
    Jentzsch, M.
    Poenisch, W.
    Michael, C.
    Heyn, S.
    Wang, S. -Y.
    Behre, G.
    Leiblein, S.
    Schwind, S.
    Niederwieser, D.
    Vucinic, V.
    HAEMATOLOGICA, 2017, 102 : 861 - 861
  • [27] The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach
    Sivina, Mariela
    Kreitman, Robert J.
    Arons, Evgeny
    Ravandi, Farhad
    Burger, Jan A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (02) : 177 - 188
  • [28] A pilot study of Bruton's tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor nivolumab in patients with metastatic solid tumors.
    Benner, Brooke
    Quiroga, Dionisia Marie
    Good, Logan
    Sun, Steven
    Savardekar, Himanshu
    Duggan, Megan Christina
    Konda, Bhavana
    Verschraegen, Claire F.
    Kendra, Kari Lynn
    Shah, Manisha H.
    Rupert, Robert
    Monk, Paul
    Shah, Hiral A.
    Noonan, Anne M.
    Bixel, Kristin Leigh
    Hays, John L.
    Behbehani, Gregory
    Pietrzak, Maciej
    Carson, William Edgar
    Wesolowski, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis over 48 Weeks: a Randomised, Placebo-controlled, Phase 2 Study
    Bojanowski, J.
    Montalban, X.
    Arnold, D. L.
    Weber, M. S.
    Staikov, I.
    Piasecka-Stryczynska, K.
    Martin, E. C.
    Syed, S.
    Dangond, F.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP69 - NP70
  • [30] Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies
    Marostica, Eleonora
    Sukbuntherng, Juthamas
    Loury, David
    Jong, Jan D.
    de Trixhie, Xavier Woot
    Vermeulen, An
    de Nicolao, Giuseppe
    O'Brien, Susan
    Byrd, John C.
    Advani, Ranjana
    McGreivy, Jesse
    Poggesi, Italo
    CANCER RESEARCH, 2014, 74 (19)
12345